[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635249":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":22,"studyPopulation":11,"armGroups":23,"interventions":49,"overallOfficials":73,"centralContacts":78,"locations":11,"responsibleParty":84,"collaborators":11,"id":86,"slug":11,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":11,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":11,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":11,"overallStatus":104,"whyStopped":11,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":11},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target knee",null,"Baseline to Week13",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","INVESTIGATOR","Osteoarthritis of the knee",[24,32,37,43],{"label":25,"type":26,"description":27,"interventionNames":28},"AD-211-L Group","EXPERIMENTAL","1 Week: twice daily; 2 tablets per dose (AD-211-L + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-L + placebo to AD-211-H + placebo to AD-2113).",[29,30,31],"Drug: AD-211-L","Drug: Placebo to AD-211-H","Drug: Placebo to AD-2113",{"label":33,"type":26,"description":34,"interventionNames":35},"AD-211-M Group","1 Week: twice daily; 2 tablets per dose AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-M + placebo to AD-211-H + placebo to AD-2113).",[36,30,31],"Drug: AD-211-M",{"label":38,"type":26,"description":39,"interventionNames":40},"AD-211-H Group","1 Week: twice daily; 2 tablets per dose (AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-H + placebo to AD-211-L\u002FM + placebo to AD-2113).",[36,41,42,31],"Drug: AD-211-H","Drug: Placebo to AD-211-L\u002FM",{"label":44,"type":45,"description":46,"interventionNames":47},"AD-2113 Group","ACTIVE_COMPARATOR","1 Week: twice daily; 2 tablets per dose (AD-2113 + placebo to AD-211-L\u002FM). 12 Weeks: twice daily; 3 tablets per dose (AD-2113 + placebo to AD-211-L\u002FM + placebo to AD-211-H).",[48,42,30],"Drug: AD-2113",[50,55,58,61,64,67,70],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"DRUG","AD-211-L","Per oral, 1 tablet twice daily during the treatment period.",[25],{"type":51,"name":56,"description":53,"armGroupLabels":57,"otherNames":11},"AD-211-M",[38,33],{"type":51,"name":59,"description":53,"armGroupLabels":60,"otherNames":11},"AD-211-H",[38],{"type":51,"name":62,"description":53,"armGroupLabels":63,"otherNames":11},"AD-2113",[44],{"type":51,"name":65,"description":53,"armGroupLabels":66,"otherNames":11},"Placebo to AD-211-L\u002FM",[38,44],{"type":51,"name":68,"description":53,"armGroupLabels":69,"otherNames":11},"Placebo to AD-211-H",[25,33,44],{"type":51,"name":71,"description":53,"armGroupLabels":72,"otherNames":11},"Placebo to AD-2113",[38,25,33],[74],{"name":75,"affiliation":76,"role":77},"Jung Yoon Choi","Daegu Catholic University Medical Center","PRINCIPAL_INVESTIGATOR",[79],{"name":80,"role":81,"phone":82,"phoneExt":11,"email":83},"Hyeji Lee","CONTACT","+82318915604","hjlee@addpharma.co.kr",{"type":85,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635249",false,"NCT07550231","Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with osteoarthritis of the Knee\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with secondary osteoarthritis of the knee\n* Other exclusions applied","ALL","19 Years","75 Years",{"count":96,"type":97},200,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.",[103],"Osteoarthritis of the Knees","NOT_YET_RECRUITING","2026-04-20",{"date":107,"type":108},"2026-04-24","ACTUAL",{"date":110,"type":97},"2026-06",{"date":112,"type":97},"2027-03",{"name":5,"class":6}]